L3VLUP
ProSign in

WST · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

WSTLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • WST
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterWSTLLY
Q3 202020 holders, $3.8bn33 holders, $14.1bn
Q4 202018 holders, $3.9bn29 holders, $17.3bn
Q1 202115 holders, $3.6bn24 holders, $23.0bn
Q2 202116 holders, $4.9bn24 holders, $27.8bn
Q3 202121 holders, $5.9bn31 holders, $29.9bn
Q4 202118 holders, $6.8bn31 holders, $34.7bn
Q1 202220 holders, $6.3bn24 holders, $35.3bn
Q2 202219 holders, $4.4bn33 holders, $42.7bn
Q3 202223 holders, $2.9bn31 holders, $43.4bn
Q4 202220 holders, $2.2bn31 holders, $46.6bn
Q1 202319 holders, $3.9bn33 holders, $44.3bn
Q2 202319 holders, $4.1bn37 holders, $59.6bn
Q3 202320 holders, $4.3bn44 holders, $67.6bn
Q4 202316 holders, $3.5bn45 holders, $73.6bn
Q1 202417 holders, $4.1bn41 holders, $95.3bn
Q2 202414 holders, $3.2bn43 holders, $110bn
Q3 202414 holders, $2.9bn45 holders, $107bn
Q4 202417 holders, $3.0bn46 holders, $93.9bn
Q1 202512 holders, $1.4bn42 holders, $98.4bn
Q2 202513 holders, $1.3bn43 holders, $93.2bn
Q3 202513 holders, $2.1bn39 holders, $86.7bn
Q4 202516 holders, $1.6bn41 holders, $123bn
Q1 202612 holders, $1.3bn39 holders, $106bn
Q2 202612 holders, $3.1bn44 holders, $132bn
WST

West Pharmaceutical SVSC Inc

Holders
17
Reported value
$4.1bn
Buyers
12
Sellers
7

Breadth +5 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
41
Reported value
$95.3bn
Buyers
15
Sellers
27

Breadth -12 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only WST (4)

Durable Capital Partners LP, ExodusPoint Capital Management LP, Maverick Capital Ltd, Winton Group Ltd

Only LLY (28)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Polen Capital Management LLC, Renaissance Technologies LLC, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Susquehanna International Group LLP, Tiger Global Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →